| P50 | author | Silvano Adami | Q114314176 |
| | Maurizio Rossini | Q41067734 |
| P2093 | author name string | Luca Idolazzi | |
| P2860 | cites work | Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study | Q46764567 |
| | Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension | Q46818517 |
| | Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results | Q46844849 |
| | Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). | Q50635496 |
| | Impact of hip and vertebral fractures on quality-adjusted life years. | Q50760212 |
| | Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. | Q50908278 |
| | Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. | Q51079439 |
| | Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. | Q52082166 |
| | A model of lifetime osteoporosis impact. | Q52441019 |
| | Antifracture efficacy of antiresorptive agents are related to changes in bone density. | Q52918360 |
| | Bias and causal associations in observational research. | Q52936961 |
| | Osteoporosis | Q57417202 |
| | Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study | Q58874870 |
| | Study designs in osteoporosis | Q73554480 |
| | Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group | Q77873031 |
| | Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents | Q77878009 |
| | Epidemiology of osteoporotic fractures | Q80559669 |
| | An estimate of the worldwide prevalence, mortality and disability associated with hip fracture | Q80874364 |
| | Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data | Q31165701 |
| | Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis | Q34003925 |
| | Osteoporosis therapies: evidence from health-care databases and observational population studies | Q34242906 |
| | Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group | Q34409983 |
| | Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial | Q34485941 |
| | Epidemiology and outcomes of osteoporotic fractures | Q34671295 |
| | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study | Q35230210 |
| | Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study | Q35637164 |
| | Osteoporosis and the global competition for health care resources. | Q35791817 |
| | Ibandronate: a clinical pharmacological and pharmacokinetic update | Q35866199 |
| | An estimate of the worldwide prevalence and disability associated with osteoporotic fractures | Q36597363 |
| | The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis | Q36700619 |
| | Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface | Q37340331 |
| | Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment | Q37400308 |
| | Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. | Q37583127 |
| | Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. | Q37616173 |
| | Time since prior fracture is a risk modifier for 10-year osteoporotic fractures | Q39895304 |
| | Adverse outcomes of osteoporotic fractures in the general population | Q40579992 |
| | Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? | Q40580002 |
| | Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group | Q41697049 |
| | Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies | Q43435539 |
| | Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. | Q43745339 |
| | Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs | Q43917199 |
| | The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis | Q44042152 |
| | Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis | Q44202451 |
| | Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. | Q44484951 |
| | Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study | Q44835560 |
| | Efficacy and safety of ibandronate given by intravenous injection once every 3 months | Q44879097 |
| | Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis | Q44879101 |
| | Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. | Q44961457 |
| | Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial | Q44961461 |
| | Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. | Q45910748 |
| | Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study | Q46148224 |
| | Mortality following fractures in older women. The study of osteoporotic fractures | Q46389938 |
| | Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study | Q46592923 |
| | Determinants of bone turnover markers in healthy premenopausal women | Q46602506 |
| | Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis | Q46672973 |
| P433 | issue | 2 | |
| P304 | page(s) | 67-79 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Therapeutic advances in musculoskeletal disease | Q26841913 |
| P1476 | title | Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review | |
| P478 | volume | 3 | |